Browse News
Filter News
Found 485,733 articles
-
Eli Lilly has signed a collaboration deal with CureVac that could total up to $1.8B.
-
Biotech stocks are generally viewed as highly volatile. Of course, along with volatility comes the possibility for huge upside rewards.
-
Two weeks after securing more than $46M in financing, Visterra struck a deal worth up to $1B with startup Vir Biotech.
-
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
-
Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.
-
The round was led by new investors as well as existing investors.
-
The good news led Ignyta's stock to jump about five percent before settling down.
-
Arthrex will build a new state-of-the-art surgical device and implant manufacturing facility in Anderson County, S.C.
-
Reckitt to Break Up Company in Restructuring
10/18/2017
The company has decided to split its business into two units - consumer healthcare and home and hygiene products -
Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.
-
Askbio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
10/18/2017
Asklepios BioPharma announced the formation of Viralgen, a gene therapy joint venture with Columbus Venture Partners.
-
Former Eli Lilly Exec Emerges as the Front-Runner for Top HHS Job
10/18/2017
Alex Azar worked at the Department of Health and Human Services under President George W. Bush before joining drugmaker Eli Lilly.
-
3 More Moderna R&D Execs Quietly Step Down
10/18/2017
So this year, Moderna has lost the head of its cancer division, its top lawyer, and its chief business officer. -
Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
10/18/2017
Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018.
-
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination With Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
10/18/2017
The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator.
-
Innovus Pharma Receives Approval from Health Canada for Vesele as a Natural Health Product
10/18/2017
Innovus Pharma announced that it has received approval from Health Canada to market its best-selling, clinically proven Vesele product as a Natural Health Product ("NHP") to help improve nitric oxide production involved in symptoms of sexual dysfunction.
-
FDA Accepts Regulatory Submission For LYNPARZA (Olaparib) In Metastatic Breast Cancer And Grants Priority Review
10/18/2017
AstraZeneca and Merck announced that FDA has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.
-
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
10/18/2017
The NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.
-
Merck's KEYTRUDA (Pembrolizumab) More Than Doubled Median Overall Survival Compared To Chemotherapy After Two Years Of Follow Up In First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer With High Levels Of PD-L1
10/18/2017
Merck announced the presentation of updated overall survival (OS) findings, a secondary endpoint, from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA (pembrolizumab).
-
Spyryx Biosciences Announces First Patient Enrolled in Phase II Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis
10/18/2017
Spyryx Biosciences today announced the first patient was dosed in the HOPE-1 study, a multinational Phase 2 clinical trial for its lead compound, SPX-101 in cystic fibrosis.